Adult mesenchymal stem cells: When, where, and how

Stem Cells International

Volumn 2015, Issue , 2015, Pages

  Caplan, Arnold I ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; STROMAL CELL DERIVED FACTOR 1;

ADULT STEM CELL; BONE MARROW TRANSPLANTATION; CELL MOTILITY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CROHN DISEASE; FECES INCONTINENCE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOLECULAR DOCKING; MULTIPLE SCLEROSIS; MUSCLE INJURY; NONHUMAN; OSTEOARTHRITIS; PARKINSON DISEASE; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; TISSUE REPAIR; TREATMENT OUTCOME;

EID: 84939148163     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2015/628767     Document Type: Review

References (43)

1. A. I. Caplan and S. E. Haynesworth, "Human mesenchymal stem cells, " Patent no. 5, 486, 359, 1996.
2. A. I. Caplan and S. E. Haynesworth, "Monoclonal Antibodies for Human Osteogenic Cell Surface Antigens, " Patent no. 5, 643, 736, 1997.
3. A. I. Caplan, "Cell delivery and tissue regeneration, " Journal of Controlled Release, vol. 11, no. 1-3, pp. 157-165, 1990.
4. A. I. Caplan, "The mesengenic process, " Clinics in Plastic Surgery, vol. 21, no. 3, pp. 429-435, 1994.
5. M. Crisan, S. Yap, L. Casteilla et al. , "A perivascular origin for mesenchymal stem cells in multiple human organs, " Cell Stem Cell, vol. 3, no. 3, pp. 301-313, 2008.
6. A. I. Caplan, "All MSCs are pericytes?" Cell Stem Cell, vol. 3, no. 3, pp. 229-230, 2008.
7. L. Da Silva Meirelles, P. C. Chagastelles, and N. B. Nardi, "Mesenchymal stem cells reside in virtually all post-natal organs and tissues, " Journal of Cell Science, vol. 119, no. 11, pp. 2204-2213, 2006.
8. C. Campagnoli, I. A. G. Roberts, S. Kumar, P. R. Bennett, I. Bellantuono, and N. M. Fisk, "Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow, " Blood, vol. 98, no. 8, pp. 2396-2402, 2001.
9. A. I. Caplan, "Whats in a name?" Tissue Engineering Part A, vol. 16, no. 8, pp. 2415-2417, 2010.
10. A. I. Caplan, "MSCs: the newmedicine, " in Stem Cells in RegenerativeMedicine: Science, Regulation, and Business Strategies, A. Vertes, Ed. , John Wiley and Sons, 2013.
11. J. E. Dick, "Acute myeloid leukemia stem cells, " Annals of the New York Academy of Sciences, vol. 1044, pp. 1-5, 2005.
12. E. A. McCulloch and J. E. Till, "The radiation sensitivity of normal mouse bone marrow cells, determined by quantitative marrow transplantation into irradiated mice, " Radiation research, vol. 13, pp. 115-125, 1960.
13. T. J. Kean, P. Lin, A. I. Caplan, and J. E. Dennis, "MSCs: delivery routes and engraftment, cell-targeting strategies, and immunemodulation, " Stem Cells International, vol. 2013, Article ID 732742, 13 pages, 2013.
14. N. G. Singer and A. I. Caplan, "Mesenchymal stem cells: mechanisms of inflammation, " Annual Review of Pathology: Mechanisms of Disease, vol. 6, pp. 457-478, 2011.
15. A. I. Caplan and J. E. Dennis, "Mesenchymal stem cells as trophic mediators, " Journal of Cellular Biochemistry, vol. 98, no. 5, pp. 1076-1084, 2006.
16. A. I. Caplan and D. Correa, "TheMSC: an injury drugstore, " Cell Stem Cell, vol. 9, no. 1, pp. 11-15, 2011.
17. M. T. Longaker and N. S. Adzick, "The biology of fetal wound healing: a review, " Plastic and Reconstructive Surgery, vol. 87, no. 4, pp. 788-798, 1991.
18. S. E. Haynesworth, D. Reuben, and A. I. Caplan, "Cell-based tissue engineering therapies: the influence of whole body physiology, " Advanced Drug Delivery Reviews, vol. 33, no. 1-2, pp. 3-14, 1998.
19. A. I. Caplan, "Adultmesenchymal stem cells for tissue engineering versus regenerative medicine, " Journal of Cellular Physiology, vol. 213, no. 2, pp. 341-347, 2007.
20. C. Maes, T. Kobayashi, M. K. Selig et al. , "Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels, " Developmental Cell, vol. 19, no. 2, pp. 329-344, 2010.
21. T. L. Bonfield, M. Koloze, D. P. Lennon, B. Zuchowski, S. E. Yang, and A. I. Caplan, "Human mesenchymal stem cells suppress chronic airway inflammation in themurine ovalbumin asthma model, " American Journal of Physiology: Lung Cellular and Molecular Physiology, vol. 299, no. 6, pp. L760-L770, 2010.
22. O. N. Koc, C. Peters, P. Aubourg et al. , "Bone marrow-derived mesenchymal stemcells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases, " Experimental Hematology, vol. 27, no. 11, pp. 1675-1681, 1999.
23. C. A. Roufosse, N. C. Direkze, W. R. Otto, and N. A. Wright, "Circulating mesenchymal stem cells, "The International Journal of Biochemistry and Cell Biology, vol. 36, no. 4, pp. 585-597, 2004.
24. M. J. Hoogduijn, M. M. A. Verstegen, A. U. Engela et al. , "No evidence for circulating mesenchymal stem cells in patients with organ injury, " Stem Cells and Development, vol. 23, no. 19, pp. 2328-2335, 2014.
25. H. E. Broxmeyer, C. M. Orschell, D. W. Clapp et al. , "Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist, " Journal of Experimental Medicine, vol. 201, no. 8, pp. 1307-1318, 2005.
26. T. A. Lane, P. Law, M. Maruyama et al. , "Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation, " Blood, vol. 85, no. 1, pp. 275-282, 1995.
27. G. Y. Rochefort, B. Delorme, A. Lopez et al. , "Multipotential mesenchymal stem cells are mobilized into peripheral blood by hypoxia, " Stem Cells, vol. 24, no. 10, pp. 2202-2208, 2006.
28. G. Moll, I. Rasmusson-Duprez, L. vonBahr et al. , "Are therapeutic human mesenchymal stromal cells compatible with human blood?" Stem Cells, vol. 30, no. 7, pp. 1565-1574, 2012.
29. J. Gao, J. E. Dennis, R. F. Muzic, M. Lundberg, and A. I. Caplan, "The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion, " Cells Tissues Organs, vol. 169, no. 1, pp. 12-20, 2001.
30. P. Lin, D. Correa, T. J. Kean, A. Awadallah, J. E. Dennis, and A. I. Caplan, "Serial transplantation and long-termengraftment of intra-arterially delivered clonally derived mesenchymal stem cells to injured bone marrow, " MolecularTherapy, vol. 22, no. 1, pp. 160-168, 2014.
31. E. D. OCearbhaill, K. S. Ng, and J. M. Karp, "Emerging medical devices for minimally invasive cell therapy, " Mayo Clinic Proceedings, vol. 89, no. 2, pp. 259-273, 2014.
32. M. S. Penn, "Importance of the SDF-1: CXCR4 axis in myocardial repair, " Circulation Research, vol. 104, no. 10, pp. 1133-1135, 2009.
33. M. S. Penn and M. K. Khalil, "Exploitation of stem cell homing for gene delivery, " Expert Opinion on BiologicalTherapy, vol. 8, no. 1, pp. 17-30, 2008.
34. M. S. Penn, F. O. Mendelsohn, G. L. Schaer et al. , "An openlabel dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure, " Circulation Research, vol. 112, no. 5, pp. 816-825, 2013.
35. S. Sundararaman, T. J. Miller, J. M. Pastore, M. Kiedrowski, R. Aras, and M. S. Penn, "Plasmid-based transient human stromal cell-derived factor-1 gene transfer improves cardiac function in chronic heart failure, " GeneTherapy, vol. 18, no. 9, pp. 867-873, 2011.
36. J. M. Hare, J. E. Fishman, G. Gerstenblith et al. , "Comparison of allogeneic vs autologous bonemarrow-derivedmesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial, " The Journal of the AmericanMedical Association, vol. 308, no. 22, pp. 2369-2379, 2012.
37. A. W. Heldman, D. L. DiFede, J. E. Fishman et al. , "Transendocardial mesenchkymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial, " The Journal of the AmericanMedical Association, vol. 322, no. 1, pp. 62-73, 2014.
38. R. G. Thorne and W. H. Frey II, "Delivery of neurotrophic factors to the central nervous system, " Clinical Pharmacokinetics, vol. 40, no. 12, pp. 907-946, 2001.
39. S. V. Dhuria, L. R. Hanson, and W. H. Frey II, "Intranasal delivery to the central nervous system: mechanisms and experimental considerations, " Journal of Pharmaceutical Sciences, vol. 99, no. 4, pp. 1654-1673, 2010.
40. L. Danielyan, R. Schäfer, A. von Ameln-Mayerhofer et al. , "Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of parkinson disease, " Rejuvenation Research, vol. 14, no. 1, pp. 3-16, 2011.
41. M. E. Bernardo and W. E. Fibbe, "Mesenchymal stromal cells: sensors and switchers of inflammation, " Cell Stem Cell, vol. 13, no. 4, pp. 392-402, 2013.
42. F. Bianchi, M. Maioli, E. Leonardi et al. , "A new non-enzymatic method and device to obtain a fat tissue derivative highly enriched in pericyte-like elements by mild mechanical forces from human lipoaspirates, " Cell Transplantation, vol. 22, no. 11, pp. 2063-2077, 2013.
43. J. Kenyon, Z. Sadeghi, S. Tomechko et al. , "Cytokine expression analysis of human MSC and injured rat tissue in a model of stress urinary incontinence, " in Proceedings of the 12th Annual ISSCR Meeting Abstract, Vancouver, Canada, June 2014.